How should an adult with a triglyceride level of 290 mg/dL be managed?

Management of Triglyceride Level of 290 mg/dL

For an adult with a triglyceride level of 290 mg/dL, initiate statin therapy immediately if the patient has diabetes, established ASCVD, or elevated cardiovascular risk, while simultaneously implementing aggressive lifestyle modifications including limiting dietary fat to ≤30% of total calories, eliminating added sugars and alcohol, and increasing physical activity. 1

Risk Stratification and Primary Target

At 290 mg/dL, this patient falls into the "mild-to-moderate hypertriglyceridemia" category (150-499 mg/dL). LDL-cholesterol must remain the primary treatment target for ASCVD risk reduction, not the triglycerides themselves 1. The triglyceride elevation serves as a marker of increased cardiovascular risk and altered lipoprotein metabolism, but lowering triglycerides alone without reducing apolipoprotein B-containing particles does not consistently reduce cardiovascular events 2.

Immediate Lifestyle Interventions

Implement these specific dietary changes immediately:

• Limit total dietary fat to ≤30-33% of total calories (approximately 40-50 grams/day for most adults) 1
• Eliminate or severely restrict: added sugars, sugary beverages, high glycemic foods, alcohol, and refined carbohydrates 3, 1
• Increase: omega-3 fatty acids from dietary sources, protein intake, and fiber 4
• Initiate moderate-to-high intensity physical activity to lower triglycerides and improve body composition 4

Address secondary causes systematically:

• Optimize glycemic control if diabetic (poor control directly elevates triglycerides) 3
• Review medications (thiazides, beta-blockers, estrogens, corticosteroids, atypical antipsychotics)
• Screen for hypothyroidism, nephrotic syndrome, and insulin resistance 3

Pharmacologic Approach

Step 1: Statin Therapy Decision

Calculate 10-year ASCVD risk using validated tools. Initiate moderate-to-high intensity statin therapy if the patient has 1:

• Established ASCVD (secondary prevention)
• Diabetes mellitus (age >40, or younger with additional risk factors)
• LDL-C >190 mg/dL
• Borderline (5-7.4%) or intermediate (7.5-19.9%) 10-year ASCVD risk
• High-risk conditions: HIV, metabolic syndrome, chronic kidney disease, chronic inflammatory diseases

The statin serves dual purposes: lowering LDL-C (primary target) and modestly reducing triglycerides (typically 10-20% reduction) 3.

Step 2: Reassess After Statin Initiation

If triglycerides remain elevated after 8-12 weeks on statin therapy:

• Verify adherence to both medication and lifestyle modifications 3
• Re-evaluate secondary causes that may have been missed
• Intensify lifestyle interventions, particularly dietary fat restriction and carbohydrate quality

Step 3: Consider Add-On Therapy (If Indicated)

For high-risk patients with persistent hypertriglyceridemia despite statin therapy, consider adding 3, 5:

• Icosapent ethyl (EPA-only) 4 grams/day: The only omega-3 formulation with proven cardiovascular benefit (25% reduction in major adverse cardiovascular events in REDUCE-IT trial) in high-risk statin-treated patients 5. This is preferred over EPA+DHA mixtures, which have not shown cardiovascular benefit and may raise LDL-C 2, 5.

• Prescription omega-3 fatty acids (EPA+DHA or EPA-only at 4 g/day) can reduce triglycerides by ≥30% 5

• Fibrates: Reserve primarily for preventing pancreatitis when triglycerides approach 500 mg/dL, as cardiovascular benefit is limited to specific subgroups 3, 2

Critical Pitfalls to Avoid

1. Do not treat triglycerides in isolation: The goal is reducing apolipoprotein B-containing atherogenic particles, not just the triglyceride number 2. Monitor non-HDL cholesterol and apoB if available.

2. Do not use EPA+DHA mixtures expecting cardiovascular benefit: Only icosapent ethyl (purified EPA) has demonstrated cardiovascular risk reduction 2, 5

3. Do not delay statin therapy: At 290 mg/dL, the patient likely has multiple metabolic abnormalities warranting statin therapy for ASCVD prevention 1

4. Do not ignore secondary causes: Uncontrolled diabetes, hypothyroidism, or offending medications will undermine all treatment efforts 3

Monitoring Strategy

• Recheck lipid panel in 8-12 weeks after initiating therapy
• Monitor for statin adherence and side effects
• Reassess lifestyle modification implementation
• If triglycerides rise toward 500 mg/dL, intensify interventions to prevent pancreatitis risk 3, 1

The evidence strongly supports that at this triglyceride level, the focus should be on comprehensive ASCVD risk reduction through LDL-C lowering with statins, not isolated triglyceride reduction 1, 2. Lifestyle modifications provide substantial benefit and should be implemented aggressively regardless of pharmacotherapy decisions 3, 1.